Tenders Are Invited For Pharmaceutical Products-Completion Of Non-Exclusive Discount Contracts In Accordance With Section 130A (8) Sgb V For Medicinal Products (Open House Procedures)

Pharmaceutical Products-Completion Of Non-Exclusive Discount Contracts In Accordance With Section 130A (8) Sgb V For Medicinal Products (Open House Procedures). The Procurement Requirement Of Ohv 2023 Includes All Drugs With The Active Ingredients Named In Appendix 3 Among The Conditions Of Participation (So -Called Active Ingredient List And Deadlines). The Need For Procurement Was Not Divided Into Lots. It Is An Open House Process. Insofar As Formulations Are Used In The Context Of This Announcement, Which Indicate The Division Of The Procurement Requirement Into One Or More, This Is Solely Due To The Requirements Of This Announcement Form. In This Context, Reference Is Made To The Non -Gathering Of Procurement Regulations Described Under Section 2.1. The Aok Has The Procurement Requirement Of The Open-House Procedure That Was Already Made By The Announcement Abf. Eu 2024/S 023 67957 (Second Follow-Up), Abi 2024/S 067-199292 (Third Follow-Up), Abi 2024/S 121-372200 (Fourth Follow-Up), Abi 2024/S 163-503369 (Fifth Follow-Up), Abi 2024/S 191/589829 (Sixth Follow-Up), Abi 2024 /S 213-665386 (Seventh Follow-Up), Abi 2024 /S 225-703422 (Eighth Follow-Up), Abi 2025 /S 016-46893 (Ninth Folklording) And Abi 2025 /S 016-127730 Again) In This Way, It Is Also To Be Extended For Medicinal Products With The Following Active Ingredient In The Context Of This Open House Procedure In Accordance With Section 130A (8) Sgbv: Ranibizumab (Lfd.-No. 25 Of Appendix 3 On The Conditions Of Participation) The Conditions Of Participation Was Therefore Supplemented Accordingly And Is Based On The Interested Companies-Together With The Other Procedures- Procurement Platform (See Section 5.1.11 Of This Tenth Follow -Up). The Aok Reserves The Right To Expand The Procurement Requirement Of This Open House Procedure In The Course Of The Further Procedure To Expand Further Active Ingredients. More Information On A Possible Expansion Of The Procurement Requirement Contains The Conditions Of Participation (Section A.I.4.1). Contracts For Drugs With The Above. The Active Ingredient Is Closed At The Earliest With Effect On 1.6.2025. All Discount Contracts Concluded As Part Of This Open House Procedure End Uniformly On June 30, 2025. For A Start Of Discount Contracts With The Above. Interested Companies Must Submit An Active Ingredient On 1.6.2025 At The Latest On April 17, 2025, A Complete Offer In Accordance With The Participation Documents Exclusively In Electronic Form Via The Communication Area Of ​​The Award Platform. Contracts For O. G. The Active Ingredient Will Be Closed On April 29, 2025 At The Earliest (Waiting And Breastfeeding Period). The Aok Binding The Content Of The Discount Contract For All Potential Contractual Partners. Negotiations On Contract Content Are Not Conducted. The Aok Itself